---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Economic information and modeling report. Covers Cost-effectiveness evidence and Budget impact model. 20 evidence topics quoted from 21 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary

- AD109 has no published price, and no cost-effectiveness or budget impact analysis of AD109 was identified.
- Company market sizing: the prospectus estimates approximately 80 million people with OSA in the United States aged 30 to 69 years, from a study Apnimed commissioned from Clarivate, and approximately one billion worldwide (WHO). The published Apnimed- and Clarivate-authored estimate (Sönmez et al. 2025) is 83.7 million U.S. adults aged 20 years and older in 2024, with OSA defined as an AHI4 of 5 or more events/hr (52% mild, 30% moderate, 18% severe). The two sources state different age bands. The prospectus also cites approximately 3 million new diagnoses per year (Komodo claims), approximately 23 million unique patients with an OSA diagnosis active in the healthcare system from 2019 to 2024 (IQVIA claims), and approximately 10.5 million diagnosed but untreated people. The last figure comes from an Inspire-supported National Sleep Foundation survey of 1,015 adults with self-reported diagnosis, in which approximately 31% of those diagnosed were not receiving treatment.
- Company payer research reports that payers perceive PAP non-compliance at greater than 60%; Apnimed's planned health economics and outcomes research may include real-world analyses of adherence, healthcare utilization, functional outcomes, and nocturnal oxygenation.
- Published cost-effectiveness of OSA treatments: CPAP for moderate to severe OSA had an ICER of $15,915 per QALY gained over a lifetime horizon in a Markov model (Pietzsch et al. 2011), and ICERs of $3354 (third-party payer) and $314 (societal) per QALY gained (Ayas et al. 2006). In another analysis, CPAP cost $12,495 per DALY averted from the health care system perspective and was dominant from the societal perspective (Streatfeild et al. 2019). A meta-analysis of 15 studies (34 in the systematic review) found CPAP cost-effective against other treatments collectively, against no treatment, and against oral appliances, with low certainty (Sajith Kumar et al. 2025). Hypoglossal nerve stimulation increased lifetime costs by $42,953 with an ICER of $39,471/QALY in a 5-state Markov model (Pietzsch et al. 2015). Published obesity models include OSA as a modeled outcome or complication (ICER 2025; Hoog et al. 2025; Annemans et al. 2026).
- Payer coverage of OSA treatments: Medicare initially limits CPAP coverage to a 12-week period and continues it only for beneficiaries who benefit (NCD 240.4). CMS states that beneficiaries prescribed Zepbound for moderate to severe OSA in adults with obesity should continue to receive Medicare Part D coverage, subject to the plan's utilization management requirements. An Aetna prior authorization policy for tirzepatide in OSA sets an initial authorization of 6 months and a continuation of 12 months, with continuation requiring a positive response. ICER reports that coverage was easier to obtain when a comorbidity was on the FDA label.

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm); [Sönmez et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40957495/); [National Sleep Foundation (2025)](https://www.thensf.org/wp-content/uploads/2025/03/NSF-Inpsire-Report_2025-1.pdf); [Pietzsch et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3098944/); [Ayas et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16682570/); [Streatfeild et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31403163/); [Sajith Kumar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39773265/); [Pietzsch et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4402668/); [ICER obesity final report (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf); [Hoog et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210105/); [Annemans et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42021523/); [CMS National Coverage Determination 240.4 (2008)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=226); [CMS Medicare GLP-1 Bridge FAQs (2026)](https://www.cms.gov/files/document/medicare-glp-1-bridge-expectations-faqs.pdf); [Aetna Zepbound prior authorization policy (2026)](https://www.aetna.com/products/rxnonmedicare/data/2026/Zepbound%20PA%20with%20Limit%206192-C%2008-2026%20v3.html)

<a id="topic-4.1-2"></a>

#### Product-specific economic evaluation of AD109

No evidence found.

<a id="topic-4.1-3"></a>

#### Company estimate: total addressable U.S. population

> “OSA is a highly prevalent condition, estimated to be affecting approximately 80 million people in the United States between the ages of 30-69, according to a study we commissioned from Clarivate Plc. (Clarivate).”
> “The total addressable market for Oxnimbi includes the estimated 80 million adults in the United States and approximately one billion people worldwide with OSA, encompassing both diagnosed and undiagnosed individuals according to a study we commissioned from Clarivate and the World Health Organization (the WHO), respectively.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-4.1-4"></a>

#### Apnimed- and Clarivate-authored U.S. prevalence estimate (AHI4 of 5 or more, adults aged 20 years and older)

> “OSA was defined as having an AHI4 ≥ 5 events/hr.”
> “A total of 83.7 million adults (aged 20 years and older) were estimated to be living with OSA in the US in 2024, of whom 49,459,041 (59%) were males and 34,257,378 (41%) females.”
> “The distribution of OSA severity was estimated to be 52% mild, 30% moderate, and 18% severe.”
> “I.S. and A.V.D. are employees of Clarivate Analytics. K.S.Y., J.C., and J.Y. are employees of Apnimed, Inc.”

Source: [Sönmez et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40957495/)

<a id="topic-4.1-5"></a>

#### Company estimate: diagnosed, newly diagnosed, and diagnosed untreated U.S. populations

> “Each year, approximately three million people are newly diagnosed according to Komodo Health, Inc.’s (Komodo) medical claims database. Our analysis of U.S. IQVIA Holdings Inc. (NYSE: IQV) (IQVIA) claims data indicates that over a five-year period from 2019 to 2024, approximately 23 million unique patients with a diagnosis of OSA were active within the healthcare system. Research from the National Sleep Foundation indicates that approximately 10.5 million people in the United States are diagnosed with OSA but are not currently receiving treatment.”
> “While weight loss treatments have broad appeal, they are not clinically relevant for the majority of OSA patients, as most lack a distinct approval in OSA and tirzepatide’s approved indication is limited to only those individuals with moderate-severe OSA and a comorbid diagnosis of obesity.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-4.1-6"></a>

#### Source of the diagnosed untreated estimate: Inspire-supported National Sleep Foundation survey

> “With support from Inspire Medical Systems Inc., NSF independently polled a representative, random sample of US adults to identify the public’s current understanding of and attitudes about sleep apnea”
> “The final sample was comprised of 1,015 American adults ages 18-90 years old (M = 48, SD = 18.21) who were representative of the US adult population”
> “Of the 19% of adults who have had some form of diagnostic workup, 13% reported being diagnosed; however, 4% of those diagnosed with sleep apnea say they are not currently being treated. Stated differently, approximately 31%, or over 10.5 million adults, diagnosed with sleep apnea are not currently receiving needed treatment.”

Source: [National Sleep Foundation (2025)](https://www.thensf.org/wp-content/uploads/2025/03/NSF-Inpsire-Report_2025-1.pdf)

<a id="topic-4.1-7"></a>

#### Company launch population and target patient profile

> “We intend to focus our initial launch phase of Oxnimbi, if approved, on the approximately 10.5 million people in the United States who are diagnosed with OSA but untreated, estimated based on the results of a survey conducted by the National Sleep Foundation in 2025”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “Initial target is ~10.5M diagnosed not on PAP”
> “New diagnosis rate >3M/year”
> “Diagnosed within the past 2 years”
> “Intolerant to PAP (refused or failed)”

Source: [Apnimed presentation (2026)](https://ir.apnimed.com/static-files/69419ee6-af17-4ba9-9b99-4fccd6e88177)

<a id="topic-4.1-8"></a>

#### Company payer research and planned health economics and outcomes research

> “Market research conducted by us among payers suggested that payers see a clear unmet need in OSA, as current OSA therapies are not curative and do not address the root cause of OSA. Payers also perceive non-compliance with PAP at greater than 60% and identified a quick onset of action, broad patient utility (mild to severe) and a once daily oral medication as key differentiators for Oxnimbi.”
> “Planned activities may include real-world analyses of adherence, healthcare utilization, functional outcomes, and the impact of improving nocturnal oxygenation, which are key drivers of payer decision-making in OSA.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-4.1-9"></a>

#### CPAP cost-effectiveness in a U.S. lifetime model

> “A Markov model was created to compare costs and effectiveness of different diagnostic and therapeutic strategies over a 10-year interval and the expected lifetime of the patient. The primary measure of cost-effectiveness was incremental cost per quality-adjusted life year (QALY) gained.”
> “For a patient with moderate-to-severe OSA, CPAP therapy has an incremental cost-effectiveness ratio (ICER) of $15,915 per QALY gained for the lifetime horizon.”

Source: [Pietzsch et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3098944/)

<a id="topic-4.1-10"></a>

#### CPAP cost-effectiveness from third-party payer and societal perspectives, U.S. Medicare costs

> “From a third-party payer or a societal perspective, CPAP therapy was more effective but more costly than no CPAP, with incremental cost-effectiveness ratios of $3354 or $314 per quality-adjusted life-year gained, respectively. The incremental cost-effectiveness ratio estimate was most dependent on viewpoint (varying more than 10-fold between societal and third-party payer perspectives) and choice of utility measurement method (varying more than 5-fold between the use of standard gamble and EuroQol 5D utility assessment values).”

Source: [Ayas et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16682570/)

<a id="topic-4.1-11"></a>

#### CPAP cost-effectiveness from health care system and societal perspectives, Australia

> “From the health care system perspective, estimated cost of CPAP therapy to treat OSA was $12 495 per DALY averted while from a societal perspective the effect was dominant (-$10 688 per DALY averted) meaning it costs more not to treat the problem than to treat it.”

Source: [Streatfeild et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31403163/)

<a id="topic-4.1-12"></a>

#### Meta-analysis of cost-utility studies of obstructive sleep apnea therapies

> “Thirty-four studies were included in the systematic review, fifteen qualifying for meta-analysis. CPAP was cost-effective compared to other treatments, with a INBp of $13,024 (95%CI $6,813 to $19,236), and substantial heterogeneity (I2 = 97.48%). Compared to no treatment and oral appliances (OAs), CPAP showed cost-effective INB values of $30,834 ($21,325 to $40,343) and $2,708 ($645 to $4,771) respectively.”
> “CPAP is cost effective compared to all treatments collectively, as well as specifically to OAs and no treatment though with low certainty.”

Source: [Sajith Kumar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39773265/)

<a id="topic-4.1-13"></a>

#### Hypoglossal nerve stimulation cost-effectiveness from a U.S. payer perspective, STAR trial projection

> “A 5-state Markov model was used to predict cardiovascular endpoints (myocardial infarction [MI], stroke, hypertension), motor vehicle collisions (MVC), mortality, quality-adjusted life years (QALYs), and costs.”
> “Costs were estimated to increase by $42,953, resulting in a lifetime ICER of $39,471/QALY.”

Source: [Pietzsch et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4402668/)

<a id="topic-4.1-14"></a>

#### Tirzepatide: obstructive sleep apnea as a tracked outcome in the ICER obesity model

> “Based on clinical evidence, expert opinion, and public comments, the model focused on the following obesity-related outcomes: T2D, CV disease and events, end-stage kidney disease (ESKD), cirrhosis, hip or knee replacement, and OSA.”
> “The model tracked the proportion of patients with obstructive sleep apnea and knee or hip replacement across all health states.”
> “To estimate the proportion of patients with OSA in each treatment arm over time, the baseline prevalence was adjusted using odds ratios from a study that examined BMI subgroups and OSA prevalence associations via individual patient data meta-analysis.”

Source: [ICER obesity final report (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-4.1-15"></a>

#### Tirzepatide: Lilly-funded U.S. obesity model with sleep apnea as a modeled complication

> “Modeled complications included cardiovascular events, onset of type 2 diabetes, cancer, osteoarthritis, and sleep apnea.”
> “The default analysis adopts a US commercial third‐party payer perspective.”
> “The study was funded by Eli Lilly and Company.”

Source: [Hoog et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210105/)

<a id="topic-4.1-16"></a>

#### Tirzepatide: UK obesity model with obstructive sleep apnea remission and progression

> “Key improvements over a previously published model were introduced, including modelling remission and progression of OSA, capturing realistic patterns of D&E discontinuation, incorporating HbA1c as a continuous cardiometabolic endpoint and transition to R-based implementation over VBA.”

Source: [Annemans et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42021523/)

<a id="topic-4.1-17"></a>

#### Payer coverage: labeled obstructive sleep apnea indication and access to tirzepatide

> “Insurance coverage was easier to obtain for individuals who had a comorbidity that was included on the FDA label for a medication”

Source: [ICER obesity final report (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-4.1-18"></a>

#### Payer coverage: Medicare Part D coverage of tirzepatide for obstructive sleep apnea

> “For example, beneficiaries prescribed Zepbound® for the treatment of moderate to severe obstructive sleep apnea in adults with obesity or Wegovy® to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight should continue to receive coverage through Medicare Part D.”
> “the provider will need to complete the applicable utilization management requirements through the beneficiary’s Part D plan.”

Source: [CMS Medicare GLP-1 Bridge FAQs (2026)](https://www.cms.gov/files/document/medicare-glp-1-bridge-expectations-faqs.pdf)

<a id="topic-4.1-19"></a>

#### Payer coverage: commercial prior authorization criteria for tirzepatide in obstructive sleep apnea

> “Authorization may be granted when the requested drug will be used with a reduced-calorie diet AND increased physical activity to treat moderate to severe obstructive sleep apnea (OSA) in an adult with obesity when ALL of the following criteria are met:”
> “The patient has achieved or maintained a positive response to treatment from baseline, evidenced by a decrease in OSA symptoms.”
> “Obstructive Sleep Apnea (OSA): Initial therapy DOA: 6 months; Continuation of therapy DOA: 12 months”

Source: [Aetna Zepbound prior authorization policy (2026)](https://www.aetna.com/products/rxnonmedicare/data/2026/Zepbound%20PA%20with%20Limit%206192-C%2008-2026%20v3.html)

<a id="topic-4.1-20"></a>

#### Payer coverage: Medicare coverage of CPAP after a 12-week trial

> “Coverage of CPAP is initially limited to a 12-week period to identify beneficiaries diagnosed with OSA as subsequently described who benefit from CPAP. CPAP is subsequently covered only for those beneficiaries diagnosed with OSA who benefit from CPAP during this 12-week period.”

Source: [CMS National Coverage Determination 240.4 (2008)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=226)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

No evidence found.

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

No evidence found.

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

<a id="topic-4.2.7-1"></a>

##### Summary

No budget impact model of AD109 was identified, and AD109 has no published price. The report holds evidence for these inputs of a future model:

- Eligible population: approximately 80 million U.S. people aged 30 to 69 years (prospectus) or 83.7 million U.S. adults aged 20 years and older with an AHI4 of 5 or more (Sönmez et al. 2025); approximately 23 million diagnosed patients active from 2019 to 2024, approximately 3 million new diagnoses per year, and approximately 10.5 million diagnosed but untreated (prospectus, from a National Sleep Foundation survey of 1,015 adults); and, for a PAP-intolerant or refusing population, the SynAIRgy intent-to-treat split of 411 (66.8%) with PAP intolerance and 205 (33.3%) with PAP refusal.
- Comparator and care costs: average costs of $2,105 per year for testing, appointments, treatment devices, and surgery if necessary (Frost & Sullivan 2016); payer costs per subject of $1,840 for a laboratory-based and $1,575 for a home-based diagnostic pathway (Kim et al. 2015); and an incremental lifetime cost of $42,953 for hypoglossal nerve stimulation (Pietzsch et al. 2015). The report quotes no acquisition price for tirzepatide.
- Discontinuation: across the two phase 3 trials combined, overall treatment discontinuation by Week 26 was 35.2% (227) with AD109 and 15.5% (100) with placebo, and treatment discontinuation due to treatment-emergent adverse events by Week 26 was 25.0% (163/653) and 6.7% (43/646); in the LunAIRo main cohort, overall discontinuation at month 12 was 46.5% with AD109 and 25.1% with placebo. For CPAP, termination (cessation of reimbursements) was 23.1%, 37.1%, and 47.7% after 1, 2, and 3 years among 480,000 people (Pépin et al. 2021).

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm); [Sönmez et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40957495/); [National Sleep Foundation (2025)](https://www.thensf.org/wp-content/uploads/2025/03/NSF-Inpsire-Report_2025-1.pdf); [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/); [Frost & Sullivan (2016)](https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf); [Kim et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481018/); [Pietzsch et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4402668/); [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277); [Patel et al. (2026b)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.317/8712356); [Pépin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7957656/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
